In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Setmelanotide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 332 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 91 (91 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 25 · 5 active1 more mentions it but does not test it | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Imcivree says: “Reduce excess body weight and maintain weight reduction long term”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Setmelanotide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 907812 | 96995410 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
| Adverse eventsWhole body | 5656 | 7757723 |
|---|
| Glycemic controlMetabolic and weight | 761 | 66866512 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1111 | 345345 |
|---|
| Liver fat and liver functionLiver | 77 | 17917441 |
|---|
| Kidney functionKidney and urinary | 33 | 1361351 |
|---|
| Appetite and food intakeMetabolic and weight | 35278 | 97952 |
|---|
| LipidsMetabolic and weight | 871 | 1181171 |
|---|
| MortalityWhole body | 44 | 1041031 |
|---|
| PharmacokineticsPharmacology | 211 | 93894 |
|---|
| Quality of lifeWhole body | 2323 | 6060 |
|---|
| Exercise and physical functionMusculoskeletal | 11 | 6969 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Setmelanotide differs from Alpha-melanocyte-stimulating hormone at 5 positions.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Setmelanotide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −16.5% BMI change Placebo: 3.3% Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026 | −16.1% BMI change Placebo: 0.6% Dose studied: 2.4 mg once weekly68 weeksn = 2012022 |
| Appetite and food intakeMetabolic and weightCompared as: value in the arm that got the peptide, in points | −2.73 points Hunger score change Placebo: −1.45 points Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn not reported2026 | 14.4 points |
| Adverse eventsWhole bodyCompared as: share of people in the arm that got the peptide, in % | 100% Participants with adverse events Placebo group: 90% Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026 | 80% Patients with adverse events · oral semaglutide 7 mg Dose studied: 7 mg once daily57 weeks |
−16.5%
BMI change
Placebo: 3.3%
Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026
−16.1%
BMI change
Placebo: 0.6%
Dose studied: 2.4 mg once weekly68 weeksn = 2012022
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Setmelanotide | Semaglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in percentage points | No randomized trial result 7 results from other study designs. | −0.87 percentage points HbA1c change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
Taste recognition score
Dose studied: 1.0 mg once weekly16 weeksn = 302025
−2.73 points
Hunger score change
Placebo: −1.45 points
Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn not reported2026
14.4 points
Taste recognition score
Dose studied: 1.0 mg once weekly16 weeksn = 302025
100%
Participants with adverse events
Placebo group: 90%
Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026
80%
Patients with adverse events · oral semaglutide 7 mg
Dose studied: 7 mg once daily57 weeksn = 1322020
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −18.08% hsCRP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in % | No randomized trial result 8 results from other study designs. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Cardiometabolic risk factorsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No randomized trial result 12 results from other study designs. | −61.1% Relative risk score change Placebo: −12.9% Dose studied: 2.4 mg68 weeksn = 1,5832023 |
|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in percentage points | No randomized trial result 7 results from other study designs. | 28.7 percentage points Estimated difference Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025 |
|---|
| Exercise and physical functionCardiovascularCompared as: difference from placebo, in points | No randomized trial result 1 result from other study designs. | 7.3 points estimated difference Dose studied: 2.4 mg once weekly52 weeksn = 6162024 |
|---|
| NeuroprotectionNervous system and cognitionCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 56.5% Favorable recovery Dose studied: 0.5 mgbefore and 1 week after EVTn = 1402025 |
|---|
| Body compositionMetabolic and weightCompared as: difference from placebo, in kg | No randomized trial result 2 results from other study designs. | −2.5 kg Lean body mass change Dose studied: 2.4 mg/wk24 weeksn = 1012026 |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No randomized trial result 3 results from other study designs. | −52.1% UACR change Dose studied: 2.4 mg per week24 weeksn = 1012025 |
|---|
No randomized trial result
7 results from other study designs.
−0.87 percentage points
HbA1c change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
1 result from other study designs.
−18.08%
hsCRP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
8 results from other study designs.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
12 results from other study designs.
−61.1%
Relative risk score change
Placebo: −12.9%
Dose studied: 2.4 mg68 weeksn = 1,5832023
No randomized trial result
7 results from other study designs.
28.7 percentage points
Estimated difference
Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025
No randomized trial result
1 result from other study designs.
7.3 points
estimated difference
Dose studied: 2.4 mg once weekly52 weeksn = 6162024
No randomized trial result
1 result from other study designs.
56.5%
Favorable recovery
Dose studied: 0.5 mgbefore and 1 week after EVTn = 1402025
No randomized trial result
2 results from other study designs.
−2.5 kg
Lean body mass change
Dose studied: 2.4 mg/wk24 weeksn = 1012026
No randomized trial result
3 results from other study designs.
−52.1%
UACR change
Dose studied: 2.4 mg per week24 weeksn = 1012025
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 25 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Rhythm Pharmaceuticals, Inc.205 participants15 Jul 2018 to 9 Jan 2025
Obesity Associated With Defects in Leptin-melanocortin Pathway
Rhythm Pharmaceuticals, Inc.143 participants26 Apr 2023 to est. 16 Apr 2027
Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.77 participants5 Aug 2021 to 7 Apr 2022
Healthy
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.